HRP20070146B1 - Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinaze - Google Patents
Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinazeInfo
- Publication number
- HRP20070146B1 HRP20070146B1 HRP20070146AA HRP20070146A HRP20070146B1 HR P20070146 B1 HRP20070146 B1 HR P20070146B1 HR P20070146A A HRP20070146A A HR P20070146AA HR P20070146 A HRP20070146 A HR P20070146A HR P20070146 B1 HRP20070146 B1 HR P20070146B1
- Authority
- HR
- Croatia
- Prior art keywords
- novel
- bcr
- inhibitors
- abl kinase
- aminopyrimidine derivatives
- Prior art date
Links
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- DMEGQEWPMXDRMO-UHFFFAOYSA-N 4-phenylpyrimidin-2-amine Chemical class NC1=NC=CC(C=2C=CC=CC=2)=N1 DMEGQEWPMXDRMO-UHFFFAOYSA-N 0.000 abstract 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Predmetni izum odnosi se na nove intermedijere koji su korisni u pripravi novih derivata fenil aminopirimidina. Farmaceutski pripravci koji sadrže nove derivate fenil aminopirimidina i postupak za pripravu istih. Predmetni izum posebice se odnosi na nove derivate fenil aminopirimidina opće formule (I). Novi spojevi formule mogu se koristiti u terapiji kronične mijeloidne leukemije (KML). Budući da se IC; 191 vrijednost dotičnih molekula nalazi u rasponu od 0,1 do 10,0 nm, predmetni novi spojevi potencijalno su korisni u liječenju KML.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN908CH2004 | 2004-09-09 | ||
PCT/IN2005/000243 WO2006027795A1 (en) | 2004-09-09 | 2005-07-19 | Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20070146A2 HRP20070146A2 (hr) | 2007-08-31 |
HRP20070146B1 true HRP20070146B1 (hr) | 2015-12-04 |
Family
ID=35395645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20070146AA HRP20070146B1 (hr) | 2004-09-09 | 2007-04-06 | Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinaze |
Country Status (26)
Country | Link |
---|---|
US (2) | US7910598B2 (hr) |
EP (2) | EP1786799B1 (hr) |
JP (1) | JP5184887B2 (hr) |
KR (1) | KR100948453B1 (hr) |
CN (1) | CN101068805B (hr) |
AP (1) | AP2470A (hr) |
AU (1) | AU2005281299B2 (hr) |
BR (1) | BRPI0515081B8 (hr) |
CA (1) | CA2591321C (hr) |
CY (1) | CY1113617T1 (hr) |
DK (1) | DK1786799T3 (hr) |
EA (1) | EA013328B1 (hr) |
ES (1) | ES2390227T3 (hr) |
HK (1) | HK1110588A1 (hr) |
HR (1) | HRP20070146B1 (hr) |
IL (1) | IL181811A (hr) |
MA (1) | MA28922B1 (hr) |
MX (1) | MX2007002819A (hr) |
NO (1) | NO337598B1 (hr) |
NZ (1) | NZ554361A (hr) |
PL (1) | PL1786799T3 (hr) |
PT (1) | PT1786799E (hr) |
SI (1) | SI1786799T1 (hr) |
UA (1) | UA94570C2 (hr) |
WO (1) | WO2006027795A1 (hr) |
ZA (2) | ZA200701942B (hr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
CN101031569B (zh) | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
US20110190328A1 (en) * | 2004-09-09 | 2011-08-04 | Natco Pharma Limited | Acid addition salts of (3,5-bis trifluoromethyl)-n-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
SI1786799T1 (sl) | 2004-09-09 | 2012-12-31 | Natco Pharma Limited | Novi derivati fenilaminopirimidina kot inhibitorji BCR-ABL kinaze |
US7939541B2 (en) | 2004-09-09 | 2011-05-10 | Natco Pharma Limited | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
US8735415B2 (en) | 2004-09-09 | 2014-05-27 | Natco Pharma Limited | Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
US8466180B2 (en) * | 2006-09-11 | 2013-06-18 | Syngenta Crop Protection Llc | Insecticidal compounds |
CA2668190A1 (en) * | 2006-11-03 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
MY148851A (en) * | 2006-12-14 | 2013-06-14 | Bayer Ip Gmbh | Dihydropyridine derivatives as useful as protein kinase inhibitors |
US8268850B2 (en) * | 2007-05-04 | 2012-09-18 | Irm Llc | Pyrimidine derivatives and compositions as C-kit and PDGFR kinase inhibitors |
CN101720322A (zh) * | 2007-05-04 | 2010-06-02 | Irm责任有限公司 | 作为c-kit和pdgfr激酶抑制剂的化合物和组合物 |
CN101784530A (zh) | 2007-08-22 | 2010-07-21 | Irm责任有限公司 | 作为激酶抑制剂的5-(4-(卤代烷氧基)苯基)嘧啶-2-胺化合物和组合物 |
ES2368876T3 (es) | 2007-08-22 | 2011-11-23 | Irm Llc | Derivados de 2-heteroarilaminopirimidina como inhibidores de cinasa. |
US8067422B2 (en) | 2008-03-04 | 2011-11-29 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
JP2011513380A (ja) * | 2008-03-04 | 2011-04-28 | ナトコ ファーマ リミテッド | フェニルアミノピリミジン誘導体の結晶型 |
WO2012004801A1 (en) * | 2010-07-07 | 2012-01-12 | Hetero Research Foundation | Process for imatinib mesylate |
GB2488788B (en) * | 2011-03-07 | 2013-07-10 | Natco Pharma Ltd | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
ES2761332T3 (es) | 2011-09-01 | 2020-05-19 | Novartis Ag | Compuestos y composiciones como inhibidores de la cinasa c-kit |
US9061028B2 (en) | 2012-02-15 | 2015-06-23 | Natco Pharma Limited | Process for the preparation of Nilotinib |
ES2637829T3 (es) * | 2012-06-15 | 2017-10-17 | Basf Se | Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados |
PT3389633T (pt) | 2015-12-18 | 2021-08-05 | Natco Pharma Ltd | Composições farmacêuticas compreendendo derivados de fenilaminopirimidina |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
US11767319B2 (en) | 2020-07-15 | 2023-09-26 | Third Harmonic Bio, Inc. | Crystalline forms of a selective c-kit kinase inhibitor |
TW202237097A (zh) | 2020-11-19 | 2022-10-01 | 美商第三諧波生物公司 | 選擇性c-kit激酶抑制劑之醫藥組合物及其製造及使用方法 |
CN113125689B (zh) * | 2021-03-29 | 2022-02-22 | 创芯国际生物科技(广州)有限公司 | 一种新型mtt细胞活力检测试剂盒及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015164A1 (en) * | 1997-09-23 | 1999-04-01 | Zeneca Limited | Amide derivatives for the treatment of diseases mediated by cytokines |
WO2004029038A1 (en) * | 2002-09-27 | 2004-04-08 | Novartis Ag | Novel pyrimidineamide derivatives and the use thereof |
WO2004110452A1 (en) * | 2003-06-13 | 2004-12-23 | Novartis Ag | 2-aminopyrimidine derivatives as raf kinase inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW225528B (hr) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
PL179417B1 (en) | 1993-10-01 | 2000-09-29 | Novartis Ag | Pharmacologically active derivatives of pyridine and methods of obtaining them |
ATE325113T1 (de) | 1993-10-01 | 2006-06-15 | Novartis Pharma Gmbh | Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung |
JPH08503971A (ja) | 1993-10-01 | 1996-04-30 | チバ−ガイギー アクチェンゲゼルシャフト | ピリミジンアミン誘導体及びその調製のための方法 |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
MXPA01000895A (es) * | 1998-08-04 | 2002-08-20 | Astrazeneca Ab | Derivados de amida utiles como inhibidores de la produccion de citocinas. |
GB0022438D0 (en) | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
AU2003246100A1 (en) * | 2002-06-28 | 2004-01-19 | Nippon Shinyaku Co., Ltd. | Amide derivative |
AU2003242988A1 (en) * | 2003-06-06 | 2005-01-04 | Adibhatla Kali Sathya Bhujanga Rao | Process for the preparation of the anti-cancer drug imatinib and its analogues |
SI1786799T1 (sl) | 2004-09-09 | 2012-12-31 | Natco Pharma Limited | Novi derivati fenilaminopirimidina kot inhibitorji BCR-ABL kinaze |
CA2668190A1 (en) * | 2006-11-03 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
-
2005
- 2005-07-19 SI SI200531589T patent/SI1786799T1/sl unknown
- 2005-07-19 WO PCT/IN2005/000243 patent/WO2006027795A1/en active Application Filing
- 2005-07-19 AU AU2005281299A patent/AU2005281299B2/en not_active Ceased
- 2005-07-19 NZ NZ554361A patent/NZ554361A/en not_active IP Right Cessation
- 2005-07-19 CA CA2591321A patent/CA2591321C/en not_active Expired - Fee Related
- 2005-07-19 PT PT05779775T patent/PT1786799E/pt unknown
- 2005-07-19 AP AP2007003944A patent/AP2470A/xx active
- 2005-07-19 ES ES05779775T patent/ES2390227T3/es active Active
- 2005-07-19 EA EA200700601A patent/EA013328B1/ru unknown
- 2005-07-19 UA UAA200703971A patent/UA94570C2/ru unknown
- 2005-07-19 KR KR1020077008040A patent/KR100948453B1/ko active IP Right Grant
- 2005-07-19 JP JP2007530854A patent/JP5184887B2/ja not_active Expired - Fee Related
- 2005-07-19 MX MX2007002819A patent/MX2007002819A/es active IP Right Grant
- 2005-07-19 PL PL05779775T patent/PL1786799T3/pl unknown
- 2005-07-19 CN CN2005800300912A patent/CN101068805B/zh not_active Expired - Fee Related
- 2005-07-19 EP EP05779775A patent/EP1786799B1/en active Active
- 2005-07-19 EP EP10184904.0A patent/EP2295424B1/en not_active Not-in-force
- 2005-07-19 DK DK05779775.5T patent/DK1786799T3/da active
- 2005-07-19 BR BRPI0515081A patent/BRPI0515081B8/pt not_active IP Right Cessation
-
2007
- 2007-03-05 US US11/714,565 patent/US7910598B2/en not_active Expired - Fee Related
- 2007-03-06 ZA ZA200701942A patent/ZA200701942B/xx unknown
- 2007-03-08 IL IL181811A patent/IL181811A/en active IP Right Grant
- 2007-03-22 NO NO20071521A patent/NO337598B1/no not_active IP Right Cessation
- 2007-04-06 MA MA29808A patent/MA28922B1/fr unknown
- 2007-04-06 HR HRP20070146AA patent/HRP20070146B1/hr not_active IP Right Cessation
- 2007-04-12 ZA ZA200703123A patent/ZA200703123B/en unknown
-
2008
- 2008-03-04 US US12/042,235 patent/US8183253B2/en active Active
- 2008-05-05 HK HK08104969.1A patent/HK1110588A1/xx not_active IP Right Cessation
-
2012
- 2012-09-28 CY CY20121100895T patent/CY1113617T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015164A1 (en) * | 1997-09-23 | 1999-04-01 | Zeneca Limited | Amide derivatives for the treatment of diseases mediated by cytokines |
WO2004029038A1 (en) * | 2002-09-27 | 2004-04-08 | Novartis Ag | Novel pyrimidineamide derivatives and the use thereof |
WO2004110452A1 (en) * | 2003-06-13 | 2004-12-23 | Novartis Ag | 2-aminopyrimidine derivatives as raf kinase inhibitors |
Non-Patent Citations (3)
Title |
---|
M. OGATA, ET AL.: "Synthesis and antiviral activity of sulphonamidobenzophenone oximes and sulphonamidobenzamides", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 29., no. 03., 1 March 1986 (1986-03-01), US, pages 417 - 423., XP002096176, ISSN: 0022-2623, DOI: 10.1021/jm00153a018 * |
SCHINDLER T,ET AL: "Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase.", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 289, no. 5486, 1 January 2000 (2000-01-01), US, pages 1938 - 1942, XP002229886, ISSN: 0036-8075, DOI: 10.1126/science.289.5486.1938 * |
ZIMMERMANN J ET AL: "Potent and selective inhibitors of the ABL-kinase: Phenylaminopyrimidine (PAP) derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 7, no. 2, 1 January 1997 (1997-01-01), AMSTERDAM, NL, pages 187 - 192, XP002214446, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(96)00601-4 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20070146B1 (hr) | Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinaze | |
HRP20070076A2 (hr) | Derivati pirimidina | |
TW200621262A (en) | New dihydropteridione derivatives, process for their manufacture and their use as medicament | |
TW200621777A (en) | New dihydropteridione derivatives, process for their manufacture and their use as medicament | |
HRP20151410T1 (hr) | Derivati pikolinamida kao inhibitori kinaze | |
DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
EA200900658A1 (ru) | Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами | |
EA201001682A1 (ru) | Производные фенил- и бензодиоксинилзамещенных индазолов | |
EA201101650A1 (ru) | Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний | |
MX2008005398A (es) | Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer. | |
MX2009002171A (es) | Derivados de triazol como inhibidores de cinasas. | |
UA99617C2 (ru) | Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение | |
EA200870282A1 (ru) | Производные амина | |
HRP20050710A2 (en) | Substituted n-arylheterocycles, method for production and use thereof as medicaments | |
ATE411296T1 (de) | Imidazolinderivate mit cb1-antagonistischer wirkung | |
MX2010005649A (es) | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. | |
MY155695A (en) | Quinoxalinedione derivatives | |
EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
MX2010009022A (es) | Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso. | |
TW200626593A (en) | Novel compounds | |
MY157116A (en) | Novel seh inhibitors and their use | |
MX2010004498A (es) | Derivados de ciclohexenoamida y su uso como antagonistas de trpv1. | |
DE602007001463D1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
ATE481972T1 (de) | Chinazolinon-derivate als vanilloid-antagonisten | |
GB0514811D0 (en) | Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190704 Year of fee payment: 15 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20200703 Year of fee payment: 16 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20210623 Year of fee payment: 17 |
|
PBON | Lapse due to non-payment of renewal fee |
Effective date: 20220719 |